Skip to the reading

A little clarity,
from Summer.

Explore +

The compound guides

GHK-Cu.
Look a little closer.

A copper peptide can appear in a skincare conversation and a prescription conversation. This guide explains why those conversations need their own questions.

Start a Promise Peptides consultation for GHK-Cu

Summer may earn money when readers become Promise patients.

Promise Peptides prescribes now through licensed U.S. providers. A provider reviews each request and decides; not everyone qualifies. U.S. patients only. Availability varies by state and treatment. Compounded medicines are not FDA-approved.

A fig branch, a little shade, room to read.

A fact about a cream cannot become a fact about an injection.

Start with the copper.

GHK is a chain of three amino acids, the building blocks of proteins. GHK-Cu is that chain bound to copper. In skincare, the ingredient name is often Copper Tripeptide-1. These names help identify an ingredient; they do not tell us whether a particular product is approved.

No medicine containing GHK-Cu has FDA approval. A cosmetic cream and an injectable medicine have different intended uses and different rules. The familiar sight of a name on a serum is not a safety record for an injection.

Read the form, then the finding.

Some laboratory work has studied GHK-Cu in skin cells. Human research on creams is limited, and much of it involves small studies. One small trial after laser skin treatment found no measurable improvement in wrinkles or overall skin quality. That result does not settle the question for all skin.

A finding from cells in a dish does not show what happens after someone uses a cream. Neither kind of finding establishes the effects of an injection. A search of the U.S. trial registry found no human GHK-Cu injection study as of September 30, 2026.

Topical simply means placed on the skin. When reading a claim, the first useful question is whether the study tested the same ingredient in the same form. A similar name can hide a very different experiment.

Separate forms, separate rules.

The FDA’s page current as of April 22, 2026, lists GHK-Cu for injectable routes as “nominated but withdrawn.” That describes a withdrawn request to consider it for compounding. It does not mean the FDA cleared it or approved an injection.

The agency’s stated concerns include impurities and immune reactions, where the body responds to a peptide as an invader. Non-injected GHK-Cu has a separate compounding-list history. It cannot be used to explain away the injectable entry.

A skin goal still needs a personal review.

Promise offers GHK-Cu consultations. A provider reviews each request and decides whether to prescribe. Compounded GHK-Cu is not FDA-approved, and a pharmacy separately considers whether it can lawfully prepare a prescription.

  • Are we discussing a cosmetic or a medicine?
  • Does the human evidence match this exact form?
  • Which safety questions have no clear answer yet?

For a broader look at the words around skin care, visit skin and peptides. An appealing ingredient name is a starting point for questions, not evidence of a skin result.

Read a little further.

When a question needs a provider.

A consultation is a place for a licensed review of your health. It can end without a prescription. There is room for that answer too.

Start a Promise Peptides consultation for GHK-Cu

Summer may earn money when readers become Promise patients.

Promise Peptides prescribes now through licensed U.S. providers. A provider reviews each request and decides; not everyone qualifies. U.S. patients only. Availability varies by state and treatment. Compounded medicines are not FDA-approved.